Diseases, Conditions, Syndromes

COVID-19 case fatality rate 29 percent in multiple myeloma patients

(HealthDay)—For patients with multiple myeloma and COVID-19, the case fatality rate is 29 percent among hospitalized patients, with increased odds of adverse outcomes among racial/ethnic minorities, according to a study ...

Oncology & Cancer

Colorado tool, My-DST, may pick best multiple myeloma treatment

In 1844, multiple myeloma was first treated with a rhubarb pill and an infusion of orange peel. Since then, more than 15 drugs have earned FDA approval to treat multiple myeloma and with so many options, a major question ...

Oncology & Cancer

New CAR-T target yields promising results for multiple myeloma

Too many patients with cancers like multiple myeloma relapse after treatment. This grim reality motivated researchers at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) to try to improve the depth and durability ...

Oncology & Cancer

Researchers identify potential formula for blood cancer vaccine

Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way to move precision immunotherapy forward by using genomics to inform immunotherapy for multiple myeloma, a blood cancer, according to a study ...

Medications

New cancer inhibitor effective where others fail

A novel agent called Selinexor has opened up new options for the treatment of patients with refractory myeloma. This was the conclusion of a major international clinical trial in which also the Karl Landsteiner University ...

Oncology & Cancer

Lenalidomide may delay onset of myeloma-related bone, organ damage

The largest randomized trial in asymptomatic patients with smoldering multiple myeloma suggests that lenalidomide, a cancer drug, may delay the onset of bone and other myeloma-related organ damage. Results of the study, which ...

page 12 from 36